Cellular Dynamics, Roche Update Alliance Covering Cardiotoxicity Platform

The two-year agreement, which took effect in March 2009 to substantiate CDI's iCell Cardiomyocytes as a predictive tool, was completed early, and the platform will now be incorporated into Roche's drug development decision-making process.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories